David Seeberger has extensive experience in publicly-listed growth-oriented biotech and medtech companies. Before taking charge of global finance operations at iOnctura, he served as VP Head of Finance Europe at NASDAQ listed bluebird bio, and held senior financial positions at Aegerion Pharmaceuticals, InterMune Corporation and Stryker Corporation.
“David has joined iOnctura at an exciting and expansive time in the company’s development,” said Catherine Pickering, CEO of iOnctura. “As our clinical programs and commercial ambitions step through the gears, his appreciation of the wider strategic life sciences landscape and proven track record in driving early businesses forward will be invaluable.”
iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.